1. Home
  2. GBIO vs EARN Comparison

GBIO vs EARN Comparison

Compare GBIO & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • EARN
  • Stock Information
  • Founded
  • GBIO 2016
  • EARN 2012
  • Country
  • GBIO United States
  • EARN United States
  • Employees
  • GBIO N/A
  • EARN N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • EARN Real Estate Investment Trusts
  • Sector
  • GBIO Health Care
  • EARN Real Estate
  • Exchange
  • GBIO Nasdaq
  • EARN Nasdaq
  • Market Cap
  • GBIO 145.5M
  • EARN 177.0M
  • IPO Year
  • GBIO 2020
  • EARN 2013
  • Fundamental
  • Price
  • GBIO $2.49
  • EARN $6.92
  • Analyst Decision
  • GBIO Buy
  • EARN Hold
  • Analyst Count
  • GBIO 4
  • EARN 2
  • Target Price
  • GBIO $7.50
  • EARN $6.00
  • AVG Volume (30 Days)
  • GBIO 63.7K
  • EARN 374.0K
  • Earning Date
  • GBIO 08-07-2024
  • EARN 08-12-2024
  • Dividend Yield
  • GBIO N/A
  • EARN 13.82%
  • EPS Growth
  • GBIO N/A
  • EARN 102.38
  • EPS
  • GBIO N/A
  • EARN 0.23
  • Revenue
  • GBIO $13,174,000.00
  • EARN $18,419,000.00
  • Revenue This Year
  • GBIO $99.36
  • EARN N/A
  • Revenue Next Year
  • GBIO N/A
  • EARN $51.24
  • P/E Ratio
  • GBIO N/A
  • EARN $29.84
  • Revenue Growth
  • GBIO 1397.05
  • EARN N/A
  • 52 Week Low
  • GBIO $0.86
  • EARN $5.09
  • 52 Week High
  • GBIO $4.72
  • EARN $7.26
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 48.59
  • EARN 50.09
  • Support Level
  • GBIO $2.13
  • EARN $6.76
  • Resistance Level
  • GBIO $2.49
  • EARN $7.04
  • Average True Range (ATR)
  • GBIO 0.24
  • EARN 0.10
  • MACD
  • GBIO -0.02
  • EARN -0.01
  • Stochastic Oscillator
  • GBIO 44.44
  • EARN 48.44

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.

Share on Social Networks: